‹¤“¯Œ¤‹†
 2010 2009 2008 2007 2006 2005 
2004 2003 2002 2001 2000 1999
1997 1996 1995 1994 1993 1992

1991 1990 1989 1988 

2019

Fujishima N, Uchida T, Onishi Y, Jung CW, Goh YT, Ando K, Wang MC, Ono C, Matsumizu M, Paccagnella ML, Sleight B, Vandendries E, Fujii Y, Hino M.
@
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.

Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.
@
Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Fuji S, Oshima K, Ohashi K, Sawa M, Saito T, Eto T, Tanaka M, Onizuka M, Nakamae H, Shiratori S, Ozawa Y, Hidaka M, Nagamura-Inoue T, Tanaka H, Fukuda T, Ichinohe T, Atsuta Y, Ogata M.
@
Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.

Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y
@
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, Nakamae H, Ikegame K, Kosaka Y, Shimada A, Nawa Y, Makoto Y, Yoshiko A, Fukuda T, Tanaka J, Ogata M.
@
Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide

Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
@
Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease

Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
@
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia

Nakasone H, Kawamura K, Yakushijin K, Shinohara A, Tanaka M, Ohashi K, Ota S, Uchida N, Fukuda T, Nakamae H, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Inamoto Y, Seo S, Kimura F, Ogata M
@
BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient

Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A.
@
BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient

Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S
@
Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience

Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.
@
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma

Fujiwara SI, Kanda J, Tatara R, Ogawa H, Fukuda T, Okumura H, Ohashi K, Iwato K, Ueda Y, Ishiyama K, Eto T, Matsuoka KI, Nakamae H, Onizuka M, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
@
Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation

Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation
@
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors

Konuma T, Harada K, Yamasaki S, Mizuno S, Uchida N, Takahashi S, Onizuka M, Nakamae H, Hidaka M, Fukuda T, Ohashi K, Kohno A, Matsushita A, Kanamori H, Ashida T, Kanda J, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
@
Upfront allogeneic HCT vs remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: a propensity score matched analysis

 

2018

Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J
@
HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome

Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara SI, Muroi K, Mori T, Kasama K, Iseki T, Nagamura-Inoue T, Fujii N, Ashida T, Kameda K, Kanda J, Hirose A, Takahashi T, Nagai K, Minakawa K, Tanosaki R
@
Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study..

Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, Najima Y, Kanamori H, Ota S, Nakamae H, Nakamae M, Mizuno I, Sugita J, Onishi Y, Yokota A, Takahashi S, Kanda Y, Ichinohe T, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
@
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)..

Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan
@
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.

Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators
@
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y
@
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

Yamamoto C, Ogawa H, Fukuda T, Igarashi A, Okumura H, Uchida N, Hidaka M, Nakamae H, Matsuoka KI, Eto T, Ichinohe T, Atsuta Y, Kanda Y.
@
Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation

Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y
@
Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F
@
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H
@
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K.
@
Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.

Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
@
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

Kirito K, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, Gadbaw B, Yamauchi K, Amagasaki T, Ito K, Hino M.
@
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

 

2017

Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y
@
Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

Fuji S, Kim SW, Kamiya S, Nakane T, Matsumoto K, Onishi Y, Yakushijin K, Yamazaki E, Hino M, Kurosawa S, Yoshimura KI, Fukuda T
@
A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimen.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.
@
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H
@
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
@
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K.
@
Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.

Kirito K, Suzuki K, Miyamura K, Takeuchi M, Handa H, Okamoto S, Gadbaw B, Yamauchi K, Amagasaki T, Ito K, Hino M.
@
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.
@
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study)..

Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, Sakai R, Ishikawa T, Izutsu K, Ueda R, Tobinai K
@
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma..

Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K..
@
Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K..
@
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

ÜŒ´ŸŒÈCŒá‹½_ŒúC‰œŽR”üŽ÷C—Ž‡—ºˆêCàV@³ŽjC“c–ìú±—²“ñC‹Êˆä‰ÀŽqC–L“ˆ’“¿C’†”öN•vC“ú–ì‰ë”VC‹{ú±‘׎iC_“c‘PLC‹àX•½˜a
@“ú–{œ‘ƒoƒ“ƒNƒhƒi[‚Ì‚Q‰ñœ‘’ñ‹Ÿ‚ÉŠÖ‚·‚錟“¢
“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïŽGŽ6(2): 108-114

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M.
@
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.

Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J.
@
Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.

Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T.
@
Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.

Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J.
@
Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T.
@
Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.

 

2016

Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T.
@
Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.

Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M.
@
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.

 

Kasashima H, Yashiro M, Nakamae H, Kitayama K, Masuda G, Kinoshita H, Fukuoka T, Hasegawa T, Nakane T, Hino M, Hirakawa K, Ohira M.
@
CXCL1-Chemokine (C-X-C Motif) Receptor 2 Signaling Stimulates the Recruitment of Bone Marrow-Derived Mesenchymal Cells into Diffuse-Type Gastric Cancer Stroma.

Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Imada K, Iwato K, Ichinohe T, Atsuta Y, Takami A, Yano S
@
Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: a Nationwide Survey by the Adult Aml Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J.
@
Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Maeda Y, Nishimori H, Inamoto Y, Nakamae H, Sawa M, Mori Y, Ohashi K, Fujiwara SI, Tanimoto M..
@
Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Konuma T, Miyazaki Y, Uchida N, Ohashi K, Kondo T, Nakamae H, Takahashi S, Mori T, Ozawa Y, Kato C, Iwato K, Fukuda T, Ichinohe T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation
@
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.

¬™@’qAŽÄŽR_•FA’†’J‰pmA–Ø“c@‹œA‘¾“cŒ’‰îA‹àŽqmbA”ª–؏G’jA“c’†G˜aA•£“c^ˆêA’†’J@ˆ»A¬—ѐ³sA•“cƒ–çAã’Ò—R—¢A‹›“ˆL•FA‘«—§—zŽqA’Ê“°@–žA“‡èçqA–쑺¹ìA“ú–ì‰ë”VA¼‘º@“žA’J˜e‰ëŽjA‹à‘q@÷A‚ÜWŽj
@Waldenstroemƒ}ƒNƒƒOƒƒuƒŠƒ“ŒŒÇ×–E‚Ì‹NŒ¹‚Ɛi“W

—Տ°ŒŒ‰t@2016 vol 57 No7 839-847

Yoshida C, Nakamae H, Fletcher L, Koga D, Sogabe T, Matsumura I, Kanakura Y, Branford S, Naoe T.
@
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ
@
Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H
@
Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Nakata-Yamada K, Inoue M, Ioka A, Ito Y, Tabuchi T, Miyashiro I, Masaie H, Ishikawa J, Hino M, Tsukuma H; and the Osaka Cancer Association for Children, Adolescents and Young Adults.
Comparison of survival of adolescents and young adults with hematologic malignancies in Osaka, Japan

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM
@
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

 

2015

Kurosawa S, Yamaguchi T, Mori T, Kanamori H, Onishi Y, Emi N, Fujisawa S, Kohno A, Nakaseko C, Saito B, Kondo T, Hino M, Nawa Y, Kato S, Hashimoto A, Fukuda T
@
Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S; DADI Trial Group
@
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Fuji S, Kim SW, Yano S, Hagiwara S, Nakamae H, Hidaka M, Ito T, Ohashi K, Hatanaka K, Takami A, Kurosawa S, Yamashita T, Yamaguchi T, Fukuda T.
@
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F

Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N, Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y..
@
Influence of differently licensed KIR2DL1-positive natural killer cells in transplant recipients with acute leukemia: a Japanese national registry study.

Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J.
@
Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.

Arai Y, Kanda J, Nakasone H, Kondo T, Uchida N, Fukuda T, Ohashi K, Kaida K, Iwato K, Eto T, Kanda Y, Nakamae H, Nagamura-Inoue T, Morishima Y, Hirokawa M, Atsuta Y, Murata M
@
Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T
@Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Kasashima H, Yashiro M, Nakamae H, Masuda G, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, Toyokawa T, Kubo N, Tanaka H, Muguruma K, Ohira M, Nakane T, Hino M, Hirakawa K.
@Bone marrow-derived stromal cells are associated with gastric cancer progression

Nakamae H, Yoshida C, Miyata Y, Hidaka M, Uike N, Koga D, Sogabe T, Matsumura I, Kanakura Y, Naoe T
@A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits

Minamino H, Machida H, Tominaga K, Morimoto K, Ominami M, Fukunaga S, Hosomi S, Hayashi Y, Nagami Y, Sugimori S, Kamata N, Shiba M, Nakamae H, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y, Ohsawa M, Hino M, Arakawa T
@Rectal biopsy, rather than ileal, is appropriate to confirm the diagnosis of early gastrointestinal graft-versus-host disease.

Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, Ozawa Y, Aotsuka N, Kouzai Y, Nakamae H, Ota S, Nakaseko C, Yamaguchi H, Kato K, Atsuta Y, Takami A
@Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Konuma T, Takahashi S, Uchida N, Kuwatsuka Y, Yamasaki S, Aoki J, Onishi Y, Aotsuka N, Ohashi K, Mori T, Masuko M, Nakamae H, Miyamura K, Kato K, Atsuta Y, Kato S, Asano S, Takami A, Miyazaki Y; Adult Myelodysplastic Syndrome and Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
@Effect of Granulocyte Colony-Stimulating Factor-Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan.

Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Nakamae H, Kurokawa M, Mori T, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M
@Age influences post-GVHD non-relapse mortality in adults with acute GVHD of varying severity following allogeneic hematopoietic cell transplantation.

Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y.
@Prospectively Isolated Human Bone marRow Cell-Derived MSCs Support Primitive Human CD34-Negative Hematopoietic Stem Cells

Kanda J, Ichinohe T, Fuji S, Maeda Y, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Nakamae H, Kobayashi N, Mori T, Mori SI, Morishima Y, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
@The impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: A retrospective analysis from the JSHCT

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; the Japan Febrile Neutropenia Study Group.
@Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial..

 

2014

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group..
@Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y, Kanamori H.
@Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Nakamae H, Oku E, Murata M, Eto T, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A.
@Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey.

Š|‰®@OAŽR“cNˆêA’†‰Æ´—²A‘ê‘òŒb’ÃŽqA‰ª“cŒb‘ãA“¡“c–¾ŽqA’†‘ºˆÀFAˆÀ•”‡ŽqAœA£’©¶A‹àŽqKOA“ú–ì ‰ë”V
@“–‰@‚É‚¨‚¯‚é—Տ°•ª—£—Δ^‹Û‚̃Jƒ‹ƒoƒyƒlƒ€ŒnR‹Û–ò‚ɑ΂·‚é–òÜŠ´Žó«‚Ì”äŠr

Jpn J Antibiotics 2014;67, 241-248

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; the Japan Febrile Neutropenia Study Group.
@Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial..

Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N.
@A prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.

‹{‘ºkˆêA‰ª–{^ˆê˜YA”–ˆä‹IŽqA“ú–ì‰ë”VAÔŽi_ˆêA’†¢ŒÃ’mºA‚‹´’¼lA’†’J@’†A‚‹´Œ[‘¾A“o@•×A’¼]˜aŽ÷
@ƒLƒƒƒŠƒuƒŒ[ƒ^[‚É‚æ‚鍑Û•W€’l•ÏŠ·‚ð‰Â”\‚Æ‚·‚éMajor BCR-ABL mRNA‘ª’èƒLƒbƒg‚̗Տ°«”\•]‰¿

—Տ°ŒŒ‰t 2014;55, 534-540

Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, Ikeda Y, Nakahata T, Imamura M, Kawa K, Kato S, Tanimoto M, Kanda Y, Tanosaki R, Shiobara S, Kim SW, Nagafuji K, Hino M, Miyamura K, Suzuki R, Hamajima N, Fukushima M, Tamakoshi A; for the Japan Society for @@Hematopoietic Cell Transplantation, Halter J, Schmitz N, Niederwieser D, Gratwohl A.
@PBSC collection from family donors in Japan: a prospective survey.

Sato KK, Hayashi T, Maeda I, Koh H, Harita N, Uehara S, Onishi Y, Oue K, Nakamura Y, Endo G, Kambe H, Fukuda K.
@Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study.

Fujisawa S, Nakamae H, Ogura M, Ishizawa KI, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.
@Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.

Yamamoto K, Shimada H, Koh H, Ataka S, Miki T.
@Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease

Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW.
@Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kosugi S, Fuchida S, Kobayashi M, Kaneko H, Uoshima N, Ishii K, Nomura S, Taniwaki M, Takaori-Kondo A, Shimazaki C, Tsudo M, Hino M, Matsumura I, Kanakura Y; Kansai Myeloma Forum Investigators
@Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.


 

2013

 

Kako S, Kanamori H, Kobayashi N, Shigematsu A, Nannya Y, Nakamae M, Shigeno K, Suzukawa K, Takeuchi M, Tsuzuki M, Usuki K, Hatanaka K, Ogawa K, Mitani K, Nawa Y, Hatta Y, Mizuno I, Kanda Y.
@Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia.

Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, Eto T, Nagamura-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka J.
@Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T, Imamura M, Wake A, Miura K, Hino M, Ishikawa T, Kim JS, Maeda Y, Lee JJ, Kang HJ, Lee HS, Lee JH, Izutsu K, Fukuda T, Kim CW, Yoshino T, Ohshima K, Nakamura S, Nagafuji K, Suzumiya J, Harada M, Kim CS..
@Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology

Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R.
@Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K.
@A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N
@Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T
@Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.

Sato KK, Hayashi T, Maeda I, Koh H, Harita N, Uehara S, Onishi Y, Oue K, Nakamura Y, Endo G, Kambe H, Fukuda K.
@Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study.

Tamai Y, Hasegawa A, Takamori A, Sasada A, Tanosaki R, Choi I, Utsunomiya A, Maeda Y, Yamano Y, Eto T, Koh KR, Nakamae H, Suehiro Y, Kato K, Takemoto S, Okamura J, Uike N, Kannagi M.
@Potential Contribution of a Novel Tax Epitope-Specific CD4+ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation.
Kai S, Wake A, Okada M, Kurata M, Atsuta Y, Ishikawa J, Nakamae H, Aotsuka N, Kasai M, Misawa M, Taniguchi S, Kato S.
@Double-Unit Cord Blood Transplantation after Myeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Phase II Study in Japan.

 

 

2012

Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K, Kanamaru A, Tamura K, Urabe A, Masaoka T; the Japan Febrile Neutropenia Study Group..
@Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.
Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakamae H, Taguchi J, Sakura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, Fukuda T.
@Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission
Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, Mugitani A, Ichihara H, Aoyama Y, Nishida S, Tsuboi A, Fujiki F, Tatsumi N, Nakajima H, Hino M, Kimura T, Yata K, Abe M, Oka Y, Oji Y, Kumanogoh A, Sugiyama H.
@CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Wada N, Zaki MA, Kohara M, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Inagaki H, Morii E, Aozasa K..
@Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.
Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fuji S, Tamaki H, Nakao T, Nishida S, Tsuboi A, Iida S, Hino M, Oka Y, Oji Y, Sugiyama H.
@CD48 as a novel molecular target for antibody therapy in multiple myeloma
Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD..
@Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Wilbur DS, Chyan MK, Nakamae H, Chen Y, Hamlin DK, Santos EB, Kornblit BT, Sandmaier BM.
@Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines.

‚ðƒNƒŠƒbƒN‚µ‚Ä‚¢‚½‚¾‚­‚Ƙa•¶´˜^‚ª‚²‚ç‚ñ‚¢‚½‚¾‚¯‚Ü‚·

2011

Shibata M, Ezoe S, Oritani K, Matsui K, Tokunaga M, Fujita N, Saito Y, Takahashi T, Hino M, Matsumura I, Kanakura Y.
@Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation.
Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L, Storb R, Boeckh M.
@Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact ofrecipient/donor factors, transplant conditions and myelotoxic drugs.
Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.
@Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Kodera Y, Suzuki R.
@Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M.
@Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Koh H, Hayashi T, Sato KK, Harita N, Maeda I, Nakamura Y, Endo G, Kambe H, Fukuda K
@Blood pressure components and risk for chronic kidney disease in middle-aged Japanese men: The Kansai Healthcare Study.
Koh H, Hayashi T, Sato KK, Harita N, Maeda I, Nishizawa Y, Endo G, Fujimoto WY, Boyko EJ, Hikita Y
@Visceral adiposity, not abdominal subcutaneous fat area, is associated with high blood pressure in Japanese men: the Ohtori study.
Chihara T, Wada N, Ikeda J, Fujita S, Hori Y, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
@Frequency of intravascular large B-cell lymphoma in Japan: study of the Osaka Lymphoma Study Group.
Zaki MA, Wada N, Kohara M, Ikeda J, Hori Y, Fujita S, Ogawa H, Sugiyama H, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
@Presence of B-cell clones in T-cell lymphoma.
Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
@Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K,
Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M,
Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno
R.
@A randomized comparison of four courses of standard-dose multiagent chemotherapy
versus three courses of high-dose cytarabine alone in post-remission therapy for acute
myeloid leukemia in adults: the JALSG AML201 study.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; the TARGET investigators.
@Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Wake A, Takahashi S, Takaue Y, Taniguchi S.
@Feasibility of Reduced-intensity Cord Blood Transplantation as Salvage Therapy for Graft Failure: Results of a Nationwide Survey of 80 Adult Patients.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R.
@Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study.
Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, Sugiyama H, Fukuhara S, Kanamaru A, Hino M, Kanakura Y, Morii E, Aozasa K.i‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
@Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries.

2010


Ishii K, Urase F, Nagare Y, Kimura H, Manabe M, Yagi T, Teshima H, Hayashi K, Shibano M, Tsukaguchi M, Katsurada T, Mugitani A, Kitayama H, Nomura S.
@VACOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience.
Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T.
@Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque' C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M.
 Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.
Sato KK, Hayashi T, Harita N, Koh H, Maeda I, Endo G, Nakamura Y, Kambe H, Kiyotaki CRelationship between drinking patterns and the risk of type 2 diabetes: the Kansai Healthcare Study.
Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K.
 Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.
Nakamichi N, Wada N, Kohara M, Fukuhara S, Sugiyama H, Ogawa H, Hino M, Kanamaru A, Kanakura Y, Morii E, Aozasa K.i‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
 Polymorphous lymphoproliferative disorder: a clinicopathological analysis.
Nakamae H, Kerbauy FR, Wilbur DS, Bethge W, Hamlin DK, Santos EB, Storb R, Sandmaier BM.
 Pilot study of a 213Bismuth-Labeled Anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.
Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher M, Petersen FB, Wade JC, Maris MB, Bruno B, Panse J, Petersdorf E, Woolfrey A, Maloney DG, Sandmaier BM.
@Low-dose Total Body Irradiation and Fludarabine Conditioning for HLA-Class I Mismatched Donor Stem Cell Transplantation and Immunological Recovery in Patients with Hematological Malignancies: A Multi-Center Trial.

2009

Wada N, Ikeda J, Kohara M, Ogawa H, Hino M, Fukuhara S, Kanamaru A, Sugiyama H, Kanakura Y, Morii E, Aozasa K.i‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
 Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
Nakamae H, Kirby KA, Sandmaier BM, Norasetthada L, Maloney DG, Maris MB, Davis C, Corey L, Storb R, Boeckh M.
@Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nishiguchi T, Mochizuki K, Shakudo M, Takeshita T, Hino M, Inoue Y.
@CNS complications of hematopoietic stem cell transplantation.
Gamper I, Koh KR, Ruau D, Ullrich K, Bartunkova J, Piroth D, Hacker C, Bartunek P, Zenke M.
 GAR22: a novel target gene of thyroid hormone receptor causes growth inhibition in human erythroid cells.
Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM.(Fred Hutchinson Cancer Research Center)
 Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the {alpha}-Emitting Radionuclides Bismuth-213 or Astatine-211.

2008

Tsumoto CiÁ‰»Ší“à‰Èj, Tominaga K, Okazaki H, Tanigawa T, Yamagami H, Watanabe K, Nakao T, Koh K, Watanabe T, Fujiwara Y, Yamane T, Oshitani N, Hino M, Higuchi K, Arakawa T.
@Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study.
Kizaki M, Okamoto S, Tauchi T, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y; and the TARGET Investigators.
@Current and future perspectives on the TARGET system: the registration system for Glivec((R)) established by the JSH.
Yamauchi A, Ikeda J, Nakamichi I, Kohara M, Fukuhara S, Hino M, Kanakura Y, Ogawa H,
Sugiyama H, Kanamaru A, Aozasa K.(‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
 Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a
study of the Osaka Lymphoma Study Group.
Shizusawa T, Shibayama H, Murata S, Saitoh Y, Sugimoto Y, Matsumura I, Ogawa H, Sugiyama H, Fukuhara S, Hino M, Kanamaru A, Yamauchi A, Aozasa K, Kanakura Y.(‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
 The expression of anamorsin in diffuse large B cell lymphoma: Possible prognostic biomarker for low IPI patients.
Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S.i‘åãŽs—§‘åŠw‘åŠw‰@ˆãŠwŒ¤‹†‰È×–Eî•ñŠwj
@Calcium channel blockers suppress cytokine-induced activation of human neutrophils.

2007

Yamauchi A, Fujita S, Ikeda J, Nakamichi I, Fukuhara S, Hino M, Kanakura Y, Ogawa H, Sugiyama H, Kanamaru A, Aozasa K.(‘åãƒŠƒ“ƒpŽîŒ¤‹†‰ïj
 Diffuse large B-cell lymphoma in th